Smoking and therapeutic response to clozapine in patients with schizophrenia

Biological Psychiatry

Volumn 46, Issue 1, 1999, Pages 125-129

  McEvoy, Joseph P ^a   Freudenreich, Oliver ^b   Wilson, William H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Clozapine; Nicotine; Schizophrenia; Smoking

Indexed keywords

CLOZAPINE; NICOTINE;

ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SCHIZOPHRENIA; SMOKING;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; REFERENCE VALUES; SCHIZOPHRENIA; SMOKING; TREATMENT OUTCOME;

EID: 0033027553     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00377-1     Document Type: Article

References (21)

1. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 32:1992;607-616.
2. Adler L.E., Olincy A., Waldo M., et al. Schizophrenia, sensory gating, and nicotine receptors. Schizophr Bull. 24:1998;189-202.
3. Anfang M.K., Pope H.G. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology. 134:1997;153-156.
4. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Colpicelli S.A., Flood J.G. Clozapine and metabolites Concentrations in serum and clinical findings during treatment of chronically psychotic patients . J Clin Psychopharmacol. 14:1994;119-120.
5. Dawe S., Gerada C., Russell M.A.H., Gray J.A. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology. 117:1995;110-115.
6. de Leon J., Davand M., Canuso C., White A.D., Stanilla J., Simpson G.M. Schizophrenia and smoking An epidemiological study in a state hospital . Am J Psychiatry. 152:1995;453-455.
7. Freudenreich O., McEvoy J.P., Cooper T.B. Monitoring of clozapine blood levels in the real world. J Clin Psychopharmacol. 16:1996;90-91.
8. Freudenreich O., Weiner R.D., McEvoy J.P. Clozapine induced EEG changes as a function of clozapine serum levels. Biol Psychiatry. 42:1997;132-137.
9. George T.P., Sernyak M.J., Ziedonis D.M., Woods S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 56:1995;344-346.
10. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia Relationship to psychopathology and medication side effects . Am J Psychiatry. 149:1992;1189-1994.
11. Haring C., Fleischhacker W., Schett P., Hummpel C., Barnes C., Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 147:1990;1471-1475.
12. Hughes J.R., Hatsukami O.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 143:1986;993-997.
13. LeHouezec J., Benowitz N.L. Basic and clinical pharmacology of nicotine. Clin Chest Med. 12:1991;681-699.
14. Levin E.D., Wilson W.H., Rose J.E., McEvoy J.P. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996;429-436.
15. McEvoy JP, Brown S (in press): High prevalence of smoking at first episode of presumptive schizophrenia. Am J Psychiatry.
16. McEvoy J.P., Freudenreich O., Levin E.D., Rose J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 119:1995;124-126.
17. McEvoy J.P., Freudenreich O., McGee M., VanderZwaag C., Levin E., Rose J. Clozapine decreases smoking inpatients with chronic schizophrenia. Biol Psychiatry. 37:1995;550-552.
18. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics Unique effects of clozapine . Biol Psychiatry. 40:1996;181-188.
19. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology. 18:1998;175-185.
20. VanderZwaag C., McGee M., McEvoy J.P., Freudenreich O., Wilson W.H., Cooper T.B. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 153:1996;1579-1584.
21. Woerner M.G., Mennuzza S., Kane J.M. Anchoring the BPRS An aid to improved reliability . Psychopharmacol Bull. 24:1988;112-117.